Caris Life Sciences/$CAI
1D1W1MYTD1Y5YMAX
Capital at risk
About Caris Life Sciences
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
- Ticker
- $CAI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,846
- Headquarters
- Irving, United States
- Website
- www.carislifesciences.com
CAI Metrics
BasicAdvanced
$8.5B
80.81
$0.37
-
-
Price and volume
Market cap
$8.5B
52-week high
$34.12
52-week low
$14.19
Average daily volume
5.6M
Financial strength
Current ratio
5.526
Quick ratio
4.754
Long term debt to equity
0.753
Total debt to equity
0.755
Interest coverage (TTM)
3.27%
Profitability
EBITDA (TTM)
174.025
Gross margin (TTM)
69.85%
Net profit margin (TTM)
10.62%
Operating margin (TTM)
15.49%
Effective tax rate (TTM)
-0.11%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
8.77%
Return on equity (TTM)
20.13%
Valuation
Price to earnings (TTM)
80.812
Price to revenue (TTM)
8.585
Price to book
14.32
Price to tangible book (TTM)
14.8
Price to free cash flow (TTM)
68.542
Free cash flow yield (TTM)
1.46%
Free cash flow per share (TTM)
0.437
Growth
Revenue change (TTM)
85.37%
Earnings per share change (TTM)
-102.00%
What the Analysts think about CAI
Analyst ratings (Buy, Hold, Sell) for Caris Life Sciences stock.
Analyst projections of the future price of Caris Life Sciences stock.
Bulls say / Bears say
Caris reported Q2 2026 revenue of $263.7 million, up 45% year-over-year, and raised full-year 2026 revenue guidance to $1.03–$1.04 billion, implying growth of 27–28% (Caris PR)
Caris ChromoSeq™ received MolDX approval in May 2026, securing broader Medicare coverage for its whole genome tumor profiling assay in myeloid malignancies and enhancing its reimbursement and market access (PR Newswire)
An interim readout of the Achieve 1 study demonstrated Caris Detect’s multi-cancer early detection test achieved up to 99.1% sensitivity in Stage IV and specificity over 99% in an asymptomatic screening population, validating its clinical performance and differentiation from methylation-based rivals (Reuters)
Management warned that demand for Caris Detect may outstrip current lab capacity, risking back orders that could constrain the near-term revenue ramp of its newly launched multi-cancer early detection test (Investing.com)
Caris relies heavily on Medicare MolDX and NGS NCD reimbursement pathways; any modification or withdrawal of CMS’s NCD coverage could materially impede revenues for key assays like ChromoSeq and Caris Detect (Form 10-K)
The company faces intense competition from established molecular profiling firms such as Guardant Health, Foundation Medicine and Exact Sciences, which may pressure pricing power and market share in both tissue- and blood-based testing markets (SEC 10-K)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2026.
CAI Financial Performance
Revenues and expenses
CAI Earnings Performance
Company profitability
Upcoming events
No upcoming events
CAI News
AllArticlesVideos
Funds containing CAI
AllUSDGBPEUR
Fund name | Fund size | $CAI weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.58% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.58% |
iShares Healthcare Innovation$HEAL | $1.4B | 0.44% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.44% |
iShares Healthcare Innovation£DRDR | £1B | 0.44% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.